Enterprise Value
174.9M
Cash
46.81M
Avg Qtr Burn
-8.022M
Short % of Float
3.51%
Insider Ownership
4.44%
Institutional Own.
38.36%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
OpRegen® (RPE Cells) Details Dry eye disease , Age-related macular degeneration | Phase 2a Update | |
OPC1 (Oligodendrocytes) Details Spine disorder, Spinal cord injury | Phase 1 Interim update | |
VAC2 (Dendritic Cells) Details Non-small cell lung carcinoma, Lung cancer, Lung disease | Phase 1 Interim update |